Sawai Pharmaceutical Co., Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Sawai Pharmaceutical Co., Ltd.
Japanese player Towa Pharmaceutical joined Sawai in capitalizing on Nichi-Iko’s misery by taking market share from its rival, as it ran factories at full capacity and plotted for further expansion.
Sawai was strong in Japan and weak in the US in the first financial quarter of its 2022 financial year, as analysts called on the Japanese firm to improve supply capacity as a “crucial first step towards expanding market share.”
Sawai is lining up eight launches as part of the Japanese company’s strategy to capture an increased share of its domestic generics market.
Japan’s Sawai has laid out its mid- and long-term ambitions in a new company business plan, spanning both its local and overseas operations.
- Generic Drugs
- Other Names / Subsidiaries
- Cambridge Biotechnology Ltd (CBT)
- Minster Pharmaceuticals
- Proximagen Group
- Upsher-Smith Laboratories Inc.
- Medisa Shinyaku Inc. and Kaken Shoyaku Inc.